Predictmedix AI Announces Non-Brokered Private Placement

Rhea-AI Summary

Predictmedix AI (CSE: PMED; OTC Pink: PMEDF) announced a proposed non‑brokered private placement to issue up to 18,000,000 units at C$0.05 per unit for gross proceeds up to C$900,000. Each Unit includes one common share and one half warrant; each whole warrant permits purchase of one common share at C$0.15 and expires in 36 months, subject to an acceleration clause if the 4‑month VWAP test exceeds $0.30 for 10 consecutive trading days.

Proceeds are intended to fund the Predictmedix Core AI Engine, clinical trial applications, SmartHealth AI station certification, B2C mobile platform development, and public‑company functions.

Positive

• C$900,000 targeted in fresh capital
• Funds earmarked to advance Core AI Engine and product verticals
• Proceeds to support clinical trial applications and certification initiatives

Negative

• Up to 18,000,000 units issued could cause material dilution
• Warrant exercise price at C$0.15 increases potential shareholder dilution
• Acceleration clause if VWAP ≥ $0.30 may shorten warrant timing and affect share count

Toronto, Ontario--(Newsfile Corp. - October 20, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, announces a proposed non brokered private placement. The Company intends to issue (the "Offering") of up to 18,000,000 units (each, a "Unit") at a price of C$0.05 per Unit, for aggregate gross proceeds to the Company of up to C$900,000.

Each Unit will be comprised of one common share of the Company (each, a "Common Share") and one half of one common share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one half Common Share of the Company at a price of C$0.15 for a period of 36 months following the closing date of the Offering. If, following four months and a day after the Closing Date, the volume weighted average price of the Common Shares on the CSE is equal to or greater than $0.30 for any 10 consecutive trading days, the Corporation may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

Strategic Direction

The capital raised is expected to strengthen Predictmedix's core AI technology and support ongoing initiatives across its product ecosystem. The company continues to advance its Predictmedix Core AI Engine, which serves as the foundation for multiple growth verticals, including:

1. AI-Powered Clinical Trial Applications

2. SmartHealth AI Station Certification Initiatives

3. B2C Vital-Scanning Mobile Platform Development

Predictmedix also intends to maintain focus on key corporate functions that support its public-company operations, regulatory compliance, and investor engagement.

Recent Corporate Activity

Following the company's successful participation at 25th MK Investment Conference in Munich, Predictmedix engaged with a number of global investors and partners who expressed strong interest in its AI-driven approach to healthcare innovation.

"The investor engagement and strategic discussions in Munich validated the global relevance of our AI technology," said Dr. Rahul Kushwah, COO of Predictmedix Inc. "This financing provides additional flexibility as we continue to strengthen our platform, explore new partnerships, and scale commercialization opportunities."

Details of the company's recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: https://predictmedix.com/press-releases/

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Smarthealth AI stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Contact
Dr. Rahul Kushwah, COO
rahul@predictmedix.com
(647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271002

FAQ

What is the size and price of Predictmedix AI's October 20, 2025 private placement (PMEDF)?

The company intends to issue up to 18,000,000 units at C$0.05 per unit for up to C$900,000 in gross proceeds.

What does each Predictmedix (PMEDF) unit include and what are the warrant terms?

Each unit includes one common share and one half warrant; each whole warrant allows purchase of one share at C$0.15 and expires in 36 months.

How will Predictmedix AI use the proceeds from the private placement (PMEDF)?

Proceeds are intended to strengthen the Core AI Engine, fund clinical trial applications, advance certification initiatives, and support B2C platform development and public‑company functions.

Could the October 2025 offering materially dilute Predictmedix shareholders (PMEDF)?

Yes; issuance of up to 18,000,000 units plus warrant exercises at C$0.15 could increase the share count and dilute existing shareholders.

What is the warrant acceleration trigger in Predictmedix's private placement (PMEDF)?

If, after four months plus one day, the 4‑month VWAP is ≥ $0.30 for any 10 consecutive trading days, the company may accelerate warrant expiry to 30 days after notice.

Did Predictmedix cite investor interest before the private placement (PMEDF)?

The company referenced investor and partner engagement following its participation at the 25th MK Investment Conference in Munich.